Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
2026 Hair Loss Treatment Updates: Oral Minoxidil, JAK Inhibitors, and Advances in FFA/LPP
Description
The talk reviewed 2026 updates in hair loss treatment, focusing on oral minoxidil, JAK inhibitors for alopecia areata, and newer approaches for frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP). Oral minoxidil was presented as a practical, widely used alternative to topical minoxidil because it is better tolerated for long-term use, has more reliable activation through liver sulfation, and may improve adherence since patients prefer pills. It can increase hair density and diameter, but clinicians should counsel about common side effects such as hypertrichosis, initial shedding, lightheadedness, and fluid retention; the speaker emphasized starting low, monitoring carefully, and noted interest in sublingual and extended-release formulations to reduce side effects. The talk also covered use in adolescents and children, with generally good tolerance. JAK inhibitors were described as transformative for alopecia areata by interrupting immune signaling that prevents follicles from staying in anagen. The speaker reviewed available FDA-approved agents, monitoring, black box warnings, response timelines, and the importance of giving treatment enough time because some patients are late responders. Oral minoxidil may be added to speed improvement, and high IgE/atopic features may predict better response to alternative immune-targeted therapy such as dupilumab in selected patients. For FFA/LPP, the speaker stressed the possible role of environmental exposures, especially fragrances and preservatives, patch testing, and strict avoidance strategies. Low-dose naltrexone was highlighted for itch and sensitivity, topical JAK inhibitors were discussed as promising, and lasers may help with facial papules, visible veins, and pigmented changes. Overall, the message was that treatment is becoming more individualized, combining better tolerated systemic options with targeted therapies and environmental modification.
View moreConclusions
- Low-dose oral minoxidil appears to be an effective and generally well-tolerated treatment for androgenetic alopecia, with better long-term practicality and adherence than topical minoxidil.
- Oral minoxidil may also serve as a useful adjunct in alopecia areata and some scarring alopecias, especially when started early or combined with other therapies.
- The main advantages of oral minoxidil are improved compliance, sustained efficacy, and usefulness in patients who do not respond well to topical minoxidil because of sulfotransferase variability.
- Most adverse effects of low-dose oral minoxidil are manageable and predictable, with hypertrichosis, fluid retention, and occasional lightheadedness being the main concerns.
- Cardiac complications at low doses appear uncommon, but compounded formulations can introduce serious dosing errors and should be used cautiously.
- Extended-release and sublingual minoxidil formulations are promising because they may preserve efficacy while reducing cardiovascular side effects.
- JAK inhibitors have transformed the treatment of alopecia areata and should now be considered a central option for appropriately screened patients.
- Alopecia areata is driven by immune-privilege collapse and a JAK-mediated inflammatory loop, so JAK inhibition can restore hair growth by interrupting that signaling.
- Patients with alopecia areata often need prolonged treatment because meaningful responses, including eyebrow and beard regrowth, may continue to improve for one to two years or longer.
- Combining oral minoxidil with JAK inhibitors can speed visible regrowth compared with starting minoxidil later.
- Baseline IgE and atopic background may help identify alopecia areata patients who are more likely to respond to dupilumab or other Th2-targeting approaches.
- In frontal fibrosing alopecia and lichen planopilaris, contact allergy and environmental exposures appear to be important contributors, so patch testing and allergen avoidance are valuable parts of management.
- Fragrance-related allergens, preservatives, and ingredients such as linalool and benzyl salicylate are repeatedly implicated in FFA/LPP cohorts.
- Low-dose naltrexone seems to reduce itch, pain, and inflammation in FFA and LPP and may help stabilize disease in selected patients.
- Topical JAK inhibitors such as delgocitinib show early promise for improving inflammatory markers and clinical outcomes in FFA and related facial pigmentary disease.
- Laser therapies and cosmetic-directed interventions can meaningfully improve troublesome features of FFA such as facial veins and papules, which can be important quality-of-life targets.
- Olsen E et al., J Am Acad Dermatol, 1990, 22:643.
- Panchaprateep et al., Dermatol Ther (Heidelb), 2020.
- Triyangkulsri K, Suchonwanit P. Drug Des Devel Ther. 2018 Jul 27;12:2323.
- Samuel et al., Dermatol Ther (Heidelb), 2023.
- Williams, Olukoga, and Tosti. Evaluation of the Safety and Effectiveness of Oral Minoxidil in Children: A Systematic Review. Dermatology and Therapy, 2024.#10.1007/s13555-024-01197-x
- Ezzat R, Alenezi S, and Miteva M. Frontal Fibrosing Alopecia Part II: Etiopathogenesis and Management. J Am Acad Dermatol, 2025 Jan.#10.1016/j.jaad.2024.08.086
- Saminska et al. (JAAD 1989;21:553-6.)
- Madan V. Symmetric Idiopathic MicroPapular Facial Eruption or SIMPLE - Int J Trichology. 2023 Sep-Oct;15(5):208-212.